Ionis Pharmaceuticals, Inc. 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020, with fourth-quarter results for the three months ended December 31, 2020. Ionis is an RNA-targeted biotechnology company focused primarily on neurology and cardiometabolic diseases. Its marketed medicines were SPINRAZA, TEGSEDI and WAYLIVRA. In October 2020, Ionis acquired the remaining shares of Akcea Therapeutics and began integrating its operations.
Financial performance and liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Total revenue | $729.3 million | $1,122.6 million | Down $393.3 million |
| Commercial revenue | $364.7 million | $352.5 million | Up $12.2 million |
| R&D revenue | $364.6 million | $770.1 million | Down $405.5 million |
| Operating expenses | $901.3 million | $756.7 million | Up $144.6 million |
| Loss from operations | $172.1 million | Income of $365.9 million | Material deterioration |
| Net loss | $486.8 million | Net income of $303.3 million | Material deterioration |
| Net loss attributable to Ionis shareholders | $451.3 million | Net income of $294.1 million | Material deterioration |
| Basic and diluted loss per share | $3.23 | Basic EPS $2.12; diluted EPS $2.08 | Declined |
| Cash flow from operations | $35.9 million | $345.6 million | Down $309.7 million |
| Cash, cash equivalents and short-term investments | $1.892 billion | $2.500 billion | Down $607.1 million |
Approximate operating margin was negative 23.6% in 2020 versus positive 32.6% in 2019. Approximate net margin was negative 66.8% versus positive 27.0% in 2019. Product sales increased to $70.0 million from $42.3 million, primarily reflecting broader TEGSEDI and WAYLIVRA launches. SPINRAZA royalty revenue declined modestly to $286.6 million from $293.0 million.
The 2020 R&D revenue decline primarily reflected the absence of 2019 license fees of approximately $400 million, including the Pfizer vupanorsen and Novartis pelacarsen transactions. Significant 2020 R&D revenue included milestones and license fees from Pfizer, AstraZeneca, Biogen and other partners, plus a $41.2 million Alnylam arbitration award.
Fourth-quarter results
| Metric | Q4 2020 | Q4 2019 |
|---|---|---|
| Revenue | $290.3 million | $493.7 million |
| Operating expenses | $312.9 million | $233.0 million |
| Loss from operations | $22.7 million | Income of $260.7 million |
| Net loss | $341.4 million | Net income of $204.0 million |
| Loss attributable to Ionis shareholders | $340.3 million | Net income of $184.4 million |
| Basic and diluted loss per share | $2.44 | Basic EPS $1.31; diluted EPS $1.28 |
Debt and liquidity
- Outstanding principal included $309.9 million of 1% convertible senior notes maturing in November 2021 and $548.8 million of 0.125% convertible senior notes maturing in December 2024.
- The notes were convertible into approximately 4.6 million and 6.6 million shares, respectively, subject to conditions. The 0.125% notes had an effective conversion price of $123.38 after the related call spread.
- Mortgage debt was approximately $60.0 million, with the related mortgages maturing in August 2027.
- Total contractual obligations were $964.6 million, including $319.5 million due within one year. The filing states that cash and short-term investments were sufficient to fund operations in the short and long term.
- Cash decreased primarily because of the Akcea acquisition, which required $544.7 million of cash payments, including payments related to cancelled Akcea equity awards, and because of share repurchases of $90.5 million.
Material changes and unusual items
- Operating expenses included approximately $89.6 million related to the Akcea acquisition and European restructuring, including $59.3 million of accelerated non-cash stock-based compensation and $30.3 million of severance, retention and other costs.
- Ionis recorded $316.7 million of income tax expense, including a $313 million non-cash charge from establishing a valuation allowance against federal net deferred tax assets. At year-end, the company maintained a valuation allowance against all consolidated federal and state net deferred tax assets.
- The acquisition increased Ionis ownership of Akcea from 76% to 100%, eliminated the Akcea noncontrolling interest and resulted in a purchase price of $450.6 million for the shares not previously owned.
- Ionis entered into a European distribution agreement with Swedish Orphan Biovitrum for TEGSEDI and WAYLIVRA, with the transition of material distribution operations occurring in January 2021.
- Ionis repurchased approximately 1.5 million shares for $90.5 million during the first quarter of 2020 under its share repurchase program.
- Ionis initiated or advanced significant late-stage programs, including Phase 3 studies for IONIS-TTR-LRx and IONIS-APOCIII-LRx. Partner-sponsored Phase 3 programs included tofersen, tominersen and pelacarsen.
Guidance, outlook and management commentary
- Management stated that Ionis achieved its 2020 financial guidance, including revenue of $729.3 million and a year-end cash balance of approximately $1.9 billion.
- The stated strategy is to invest in the wholly owned pipeline, commercial capabilities and expansion of the antisense technology platform, with a goal of 12 or more marketed products by 2026.
- The filing does not provide a clear quantified 2021 revenue or earnings guidance.
- Management described the COVID-19 impact as limited and manageable at the filing date, but reported delays in clinical-site initiation, enrollment, patient visits and commercialization activities. Biogen also reported lower SPINRAZA sales revenue partly because doses were delayed.
- Ionis expects continued dependence on collaboration revenue, royalties, milestone payments and successful development of partnered and wholly owned medicines. The company disclosed potential future milestone, licensing and other payments exceeding $20 billion from existing partnerships, excluding royalties, but these amounts are contingent and not assured.
Key risks and contingencies
- Revenue is concentrated in collaboration partners and partnered products; Biogen represented approximately 56% of 2020 revenue, including SPINRAZA royalties and R&D revenue.
- SPINRAZA faces competition from gene therapy and oral therapies, including onasemnogene abeparvovec and risdiplam. SPINRAZA royalty revenue declined in 2020.
- TEGSEDI carries a U.S. boxed warning and REMS requirements relating to thrombocytopenia and glomerulonephritis. WAYLIVRA requires monitoring for thrombocytopenia and bleeding in the EU.
- WAYLIVRA previously received an FDA complete response letter and a Canadian non-approval decision. Additional regulatory approvals remain uncertain.
- Late-stage clinical programs may fail to demonstrate sufficient safety or efficacy, and COVID-19 may cause further delays or supply-chain disruption.
- Commercial success depends on reimbursement, pricing, market acceptance, manufacturing capacity, third-party distributors and partner performance.
- Ionis is subject to patent validity, infringement and litigation risks, as well as product liability, regulatory, tax, cybersecurity and key-personnel risks.
- A purported Akcea stockholder lawsuit alleges fiduciary-duty and unjust-enrichment claims related to licensing transactions involving TEGSEDI and IONIS-TTR-LRx. The company states that it believes the claims are without merit; the amended complaint had not yet been filed as of the report.
Important facts for investors to verify
- Whether recurring commercial revenue and SPINRAZA royalties can offset the volatility of milestone and license-fee revenue.
- The timing, cost and outcomes of Phase 3 programs for tofersen, tominersen, pelacarsen, IONIS-TTR-LRx and IONIS-APOCIII-LRx.
- The commercial performance of TEGSEDI and WAYLIVRA following the Akcea integration and European transition to Sobi.
- The cash requirements associated with the wholly owned pipeline, commercialization investments and the $309.9 million principal maturity of the 1% convertible notes in November 2021.
- The effect of the $633.4 million valuation allowance against net deferred tax assets and whether future profitability could support its reversal.
- The financial and operational benefits actually realized from acquiring Akcea, including integration costs, employee retention and commercialization execution.
- Continuing exposure to COVID-19, reimbursement restrictions, partner dependence, clinical failures, manufacturing interruptions and competitive products.